<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="PriyamvadaLalita1AlabiPhilip2LeonAndres2KumarAmrita3SambharaSuryaprakash3OlsonVictoria A.1SelloJason K.2*SatheshkumarPanayampalli S.1*[], 1Poxvirus and Rabies Branch, Centers for" exact="Disease" post="Control and PreventionAtlanta, GAUnited States[], 2Department of Chemistry, Brown"/>
 <result pre="RIUnited States[], 3Immunology and Pathogenesis Branch, Influenza Division, Centers for" exact="Disease" post="Control and PreventionAtlanta, GAUnited States Edited by: Lu Lu,"/>
 <result pre="China Reviewed by: Chen Peng, National Institute of Allergy and" exact="Infectious" post="Diseases (NIAID), United States; Carlos Maluquer De Motes, University"/>
 <result pre="Reviewed by: Chen Peng, National Institute of Allergy and Infectious" exact="Diseases" post="(NIAID), United States; Carlos Maluquer De Motes, University of"/>
 <result pre="growing population of OPXV-naive individuals after the discontinuation of routine" exact="smallpox" post="vaccination. Antiviral drugs that are effective as postexposure treatments"/>
 <result pre="vaccination. Antiviral drugs that are effective as postexposure treatments against" exact="variola" post="virus (the causative agent of smallpox) or other OPXVs"/>
 <result pre="that host Golgi-associated retrograde proteins play an important role in" exact="monkeypox" post="virus (MPXV) and vaccinia virus (VACV) EV formation. Inhibition"/>
 <result pre="proteins play an important role in monkeypox virus (MPXV) and" exact="vaccinia" post="virus (VACV) EV formation. Inhibition of the retrograde pathway"/>
 <result pre="molecules such as Retro-2 has been shown to decrease VACV" exact="infection" post="in vitro and to a lesser extent in vivo."/>
 <result pre="anti-VACV activity, causing a reduction in EV particle formation and" exact="viral" post="spread compared to Retro-1. PA104 emerged as the most"/>
 <result pre="Retro-1. PA104 emerged as the most potent analog, inhibiting 90%" exact="viral" post="spread at 1.3 μM with a high selectivity index."/>
 <result pre="important implications for the design of effective antivirals against OPXV." exact="viral" post="inhibitor poxvirus antiviral agent retrograde transport vaccinia virus Retro-1"/>
 <result pre="antivirals against OPXV. viral inhibitor poxvirus antiviral agent retrograde transport" exact="vaccinia" post="virus Retro-1 retrograde inhibitor ST-246 fig-count: table-count: equation-count: ref-count:"/>
 <result pre="genus contains several human pathogens of public health concern, including" exact="variola" post="virus (the causative agent of smallpox), monkeypox virus (MPXV),"/>
 <result pre="health concern, including variola virus (the causative agent of smallpox)," exact="monkeypox" post="virus (MPXV), cowpox virus, and vaccinia virus (VACV, the"/>
 <result pre="variola virus (the causative agent of smallpox), monkeypox virus (MPXV)," exact="cowpox" post="virus, and vaccinia virus (VACV, the virus that formulates"/>
 <result pre="causative agent of smallpox), monkeypox virus (MPXV), cowpox virus, and" exact="vaccinia" post="virus (VACV, the virus that formulates the smallpox vaccine)"/>
 <result pre="virus, and vaccinia virus (VACV, the virus that formulates the" exact="smallpox" post="vaccine) (Fenner and Nakano, 1988). While smallpox has been"/>
 <result pre="that formulates the smallpox vaccine) (Fenner and Nakano, 1988). While" exact="smallpox" post="has been eradicated, other OPXVs continue to pose a"/>
 <result pre="the lack of protective immunity post the cessation of routine" exact="smallpox" post="vaccination (Durski et al., 2018). In particular, the incidence"/>
 <result pre="the rise due to several recent outbreaks in West and" exact="Central" post="Africa after a long hiatus in reported epidemics (Durski"/>
 <result pre="et al., 2018). There is also a risk of MPXV" exact="infections" post="spreading outside the endemic region through travel or the"/>
 <result pre="core (Condit et al., 2006). Mature viruses consist of a" exact="viral" post="core and a single viral membrane and harbor all"/>
 <result pre="Mature viruses consist of a viral core and a single" exact="viral" post="membrane and harbor all the necessary proteins required for"/>
 <result pre="1–10% of MVs, they are essential for cell-to-cell and long-distance" exact="viral" post="spread and therefore play an important role in OPXV"/>
 <result pre="antiviral available for postexposure treatment against smallpox. ST-246 targets the" exact="viral" post="envelope protein F13 required for EV formation, thereby decreasing"/>
 <result pre="viral envelope protein F13 required for EV formation, thereby decreasing" exact="viral" post="spread and infection-induced pathology (Yang et al., 2005; Grosenbach"/>
 <result pre="mutations in the F13L gene, as documented in a progressive" exact="vaccinia" post="(PV) patient in 2009 (Lederman et al., 2012). A"/>
 <result pre="OPXVs require retrograde transport for EV membrane wrapping, and consequently" exact="viral" post="egress (Spooner et al., 2006; Harrison et al., 2016;"/>
 <result pre="EV formation in vitro by preventing the trafficking of the" exact="viral" post="protein F13, which is required for membrane wrapping (Harrison"/>
 <result pre="with treated mice showing marginal improvement in signs of clinical" exact="disease" post="and comparable lung viral titers compared to untreated mice"/>
 <result pre="marginal improvement in signs of clinical disease and comparable lung" exact="viral" post="titers compared to untreated mice (Harrison et al., 2016)."/>
 <result pre="to no cytotoxicity. We also show that the reduction in" exact="viral" post="spread by PA104 is attributable to inhibition of EV"/>
 <result pre="infected cells. It is particularly noteworthy that PA104 also inhibits" exact="viral" post="spread of two distinct ST-246-resistant viruses, establishing its potential"/>
 <result pre="antiviral agent. Materials and Methods Viruses, Cell Lines, and Inhibitors" exact="Vaccinia" post="virus WR-GFP, VACV WR A4-YFP, VACV WR-Luc, and VACV"/>
 <result pre="hereby be referred to as RV1 and RV2, respectively. All" exact="viral" post="stocks were titered by plaque assay prior to use"/>
 <result pre="and 100 μg/mL of streptomycin (penicillin–streptomycin). For all experiments involving" exact="viral infection," post="DMEM containing 2% FBS, hereby referred to as &quot;DMEM-2,�?"/>
 <result pre="information about the compounds can be made available upon request." exact="Viral" post="Spread Assay The viral spread assay was performed as"/>
 <result pre="can be made available upon request. Viral Spread Assay The" exact="viral" post="spread assay was performed as previously described (Cryer et"/>
 <result pre="(vol/vol) with VACV-WR-GFP virus diluted in DMEM-2 at multiplicity of" exact="infection" post="(MOI) 0.3. The mixture was transferred to black 96-well,"/>
 <result pre="Cell Analysis software as previously described (Johnson et al., 2008)." exact="Total" post="viral spread and viral spread for each compound were"/>
 <result pre="Analysis software as previously described (Johnson et al., 2008). Total" exact="viral" post="spread and viral spread for each compound were measured"/>
 <result pre="previously described (Johnson et al., 2008). Total viral spread and" exact="viral" post="spread for each compound were measured as shown below:"/>
 <result pre="�?� p �?� r �?� e �?� a �?� d" exact="Viral" post="spread data were analyzed using a non-linear regression (curve"/>
 <result pre="required for 50% inhibition (IC50) and 90% inhibition (IC90) of" exact="viral" post="spread relative to the no treatment control. Analyses were"/>
 <result pre="Eugene, OR, United States) and imaged using the LSM 710" exact="inverted" post="confocal microscope (Zeiss, Oberkochen, Germany). Virus-loaded actin tails in"/>
 <result pre="PV patient (Lederman et al., 2012) in the presence or" exact="absence of" post="ST-246. Plaques observed in the presence of ST-246 were"/>
 <result pre="a six-well plate of BSC40 cells to create an RV1" exact="viral" post="stock. To confirm the presence of the previously characterized"/>
 <result pre="vitro To identify new inhibitors of VACV infection, we quantified" exact="viral" post="spread in the presence of diverse compounds sharing a"/>
 <result pre="Retro-1 using VACV WR-GFP as shown in Figure 1A. A" exact="total" post="of 83 compounds were tested, and the percentage of"/>
 <result pre="of GFP+ cells was determined by fluorescent imaging. We measured" exact="viral" post="spread for each compound over a range of concentrations"/>
 <result pre="data not shown). In addition to examining their effect on" exact="viral" post="spread, we also assessed the cellular cytotoxicity of a"/>
 <result pre="exhibited low cytotoxicity even at 400 μM. Based on the" exact="viral" post="spread screen of the Retro-1 like benzodiazepines, we narrowed"/>
 <result pre="minimal cytotoxicity. (A) Schematic representation of steps used to determine" exact="viral" post="spread and cellular toxicity in the presence of Retro-1"/>
 <result pre="for each compound, in duplicate. (B) Representative graph showing percent" exact="viral" post="spread in the presence of a serial dilution series"/>
 <result pre="&amp;gt;570 PA24 1.0 1.8 &amp;gt;400 &amp;gt;400 Retro-1 Derivatives Inhibit VACV" exact="Infection" post="Post-entry Given the considerable reduction in viral spread described"/>
 <result pre="Derivatives Inhibit VACV Infection Post-entry Given the considerable reduction in" exact="viral" post="spread described earlier, we checked the effect of PA24,"/>
 <result pre="the RLU values in our assay were largely attributable to" exact="viral" post="entry and gene expression, rather than prepackaged luciferase. FIGURE"/>
 <result pre="We observed that PA24 and PA63 did not markedly decrease" exact="viral" post="entry at the lower concentrations tested, corroborating the findings"/>
 <result pre="and PA63 did not markedly decrease viral entry at the" exact="lower" post="concentrations tested, corroborating the findings of a previous study"/>
 <result pre="a higher concentration (10 μM) of PA24 and PA63 reduced" exact="viral" post="entry, for PA104 a decrease in viral entry was"/>
 <result pre="and PA63 reduced viral entry, for PA104 a decrease in" exact="viral" post="entry was observed at all three concentrations tested (Figure"/>
 <result pre="potent retrograde inhibitors may inhibit virus entry at high concentrations." exact="Reduced" post="EV Yield in the Presence of Retro-1 Derivatives Previous"/>
 <result pre="a reduction in EV particle formation during VACV and MPXV" exact="infection" post="(Harrison et al., 2016; Sivan et al., 2016). To"/>
 <result pre="Sivan et al., 2016). To confirm that the decrease in" exact="viral" post="spread observed earlier was attributable to a reduction in"/>
 <result pre="reduction in MV production could be due to effects on" exact="viral" post="entry (Figure 2B). The reduction in EV yield among"/>
 <result pre="tested ranged between 54 and 89% (Figure 3C). FIGURE 3" exact="Reduced" post="EV formation in the presence of Retro-1 analogs. (A)"/>
 <result pre="al., 2002). Since we had observed a decrease in both" exact="viral" post="spread and EV yield in the presence of Retro-1"/>
 <result pre="end, we infected cells with VACV in the presence or" exact="absence of" post="PA24, PA63, and PA104 and visualized actin-associated virus particles"/>
 <result pre="and visualized actin-associated virus particles using confocal microscopy. In the" exact="absence of" post="the Retro-1 inhibitors, infected cells had several actin tails"/>
 <result pre="several actin tails loaded with VACV at the tips (the" exact="viral" post="particles appear as green dots due to the fusion"/>
 <result pre="with the core protein A4), which is characteristic of VACV" exact="infection" post="(Figure 4 and Supplementary Figure S2). On the other"/>
 <result pre="in the presence of retrograde inhibitors, which results in a" exact="lower" post="EV yield overall. FIGURE 4 Inhibition of EV formation"/>
 <result pre="infected with VACV WR A4-YFP virus in the presence or" exact="absence of" post="Retro-1 analogs PA63, PA24, and PA104. Few to no"/>
 <result pre="Inhibits the Spread of ST-246-Resistant Viruses ST-246, targets F13, a" exact="peripheral" post="viral membrane protein, interfering with its intracellular localization (Yang"/>
 <result pre="the Spread of ST-246-Resistant Viruses ST-246, targets F13, a peripheral" exact="viral" post="membrane protein, interfering with its intracellular localization (Yang et"/>
 <result pre="et al., 2005). However, mutations in F13L gene can cause" exact="viral" post="resistance to ST-246 as demonstrated previously (Yang et al.,"/>
 <result pre="5A). The second virus, hereby referred to as RV2, was" exact="acquired" post="from SIGA Technologies and contains the N267D resistance mutation"/>
 <result pre="2011). FIGURE 5 Retro-1 analogs PA104, PA24, and PA63 inhibit" exact="viral" post="spread of ST-246-resistant VACV. (A) RV1 and RV2 sequence"/>
 <result pre="mutations, respectively. Amino acid alignment of F13 of lab-grown RV1" exact="viral" post="isolates and RV2 compared to published ACAM strain (Lederman"/>
 <result pre="al., 2012). (B) Plaque assay images showing observable decrease in" exact="viral" post="plaque size of RV1 and RV2 virus in the"/>
 <result pre="the ST-246-resistant viruses formed large plaques in the presence or" exact="absence of" post="2 μM ST-246, a concentration of ST-246 over 50-fold"/>
 <result pre="with PA104, PA24, and PA63 caused a considerable reduction in" exact="viral" post="plaque size. As shown in Figure 5B, all three"/>
 <result pre="the other hand, PA104 was markedly more effective in reducing" exact="viral" post="spread than PA24 and PA63 (Figure 5B). Overall, these"/>
 <result pre="The inhibitory effect was predominantly at a late stage of" exact="viral" post="replication. (iii) EV formation is the main target of"/>
 <result pre="impact on MV yield. (iv) Retro-1 analogs can effectively decrease" exact="viral" post="spread of ST-246-resistant viruses. In addition, we identified the"/>
 <result pre="yield data together suggest that while the main mechanism of" exact="viral" post="inhibition by Retro-1 derivatives is the inhibition of EV"/>
 <result pre="EV particle formation, select compounds such as PA104 may impact" exact="viral" post="entry when present at concentrations greater than their effective"/>
 <result pre="in vitro (Harrison et al., 2016; Sivan et al., 2016)." exact="Vaccinia" post="virus replicates in the cytoplasm of the infected cells,"/>
 <result pre="infected cell by actin tails (Smith et al., 2002). Because" exact="viral" post="spread and EV yield were greatly reduced in the"/>
 <result pre="different ST-246-resistant viruses and found that all three compounds reduced" exact="viral" post="spread of both viruses, as determined by a reduction"/>
 <result pre="spread of both viruses, as determined by a reduction in" exact="viral" post="plaque size. Interestingly, while RV2 was substantially inhibited by"/>
 <result pre="by PA24 and PA63. These differences in the levels of" exact="viral" post="inhibition by the same compounds could potentially be caused"/>
 <result pre="its ability to target multiple steps of VACV infection, including" exact="viral" post="entry and MV formation, in addition to EV formation"/>
 <result pre="exploration. Further, PA104 targets a host-specific process rather than a" exact="viral" post="protein, offering two additional advantages. First, the absence of"/>
 <result pre="than a viral protein, offering two additional advantages. First, the" exact="absence of" post="a direct viral target reduces the probability of viral"/>
 <result pre="offering two additional advantages. First, the absence of a direct" exact="viral" post="target reduces the probability of viral resistance to the"/>
 <result pre="absence of a direct viral target reduces the probability of" exact="viral" post="resistance to the compound (Lin and Gallay, 2013; Kaufmann"/>
 <result pre="have also investigated the effect of Retro-2 derivatives on HSV2" exact="infections" post="(Dai et al., 2018). A majority of these studies"/>
 <result pre="The authors declare that the research was conducted in the" exact="absence of" post="any commercial or financial relationships that could be construed"/>
 <result pre="study was supported by the CDC Intramural Research and Biomedical" exact="Advanced" post="Research and Developmental Authority (BARDA) and an ORISE Postdoctoral"/>
 <result pre="by the CDC Intramural Research and Biomedical Advanced Research and" exact="Developmental" post="Authority (BARDA) and an ORISE Postdoctoral Fellowship (LP) and"/>
 <result pre="not necessarily represent the official position of the Centers for" exact="Disease" post="Control and Prevention. Supplementary Material The Supplementary Material for"/>
 <result pre="be found online at: https://www.frontiersin.org/articles/10.3389/fmicb.2020.00603/full#supplementary-material FIGURE S1 Validation of luciferase-based" exact="viral" post="entry assay. (A) Minimal input luciferase activity after 5"/>
 <result pre="entry assay. (A) Minimal input luciferase activity after 5 min" exact="infection" post="at RT. Luciferase activity in cells infected for 5"/>
 <result pre="in cells infected for 5 min at RT was significantly" exact="lower" post="than infection for 2 h at 37°C. **** indicates"/>
 <result pre="infected for 5 min at RT was significantly lower than" exact="infection" post="for 2 h at 37°C. **** indicates an unpaired"/>
 <result pre="infected with VACV WR A4-YFP virus in the presence or" exact="absence of" post="Retro-1 analogs PA63, PA24, and PA104. Lower magnification images"/>
 <result pre="among international travellers-serious monkey business?.J. Travel Med.26:taz002. BlascoR.MossB. (1991). Extracellular" exact="vaccinia" post="virus formation and cell-to-cell virus transmission are prevented by"/>
 <result pre="envelope protein.J. Virol.655910–5920. 1920620 BlascoR.MossB. (1992). Role of cell-associated enveloped" exact="vaccinia" post="virus in cell-to-cell spread.J. Virol.664170–4179. 1602540 CarneyD. W.NelsonC. D.FerrisB."/>
 <result pre="optimization of a retrograde trafficking inhibitor that protects cells from" exact="infections" post="by human polyoma- and papillomaviruses.Bioorg. Med. Chem.224836–4847. 10.1016/j.bmc.2014.06.05325087050 ConditR."/>
 <result pre="C.MoussatcheN.TraktmanP. (2006). In a nutshell: structure and assembly of the" exact="vaccinia" post="virion.Adv. Virus Res.6631–124. 16877059 CraigE.Huyghues-DespointesC. E.YuC.HandyE. L.SelloJ. K.KimaP. E."/>
 <result pre="identification of compounds from Kalanchoe pinnata having human alphaherpesvirus and" exact="vaccinia" post="virus antiviral activity.Pharm. Biol.551586–1591. 10.1080/13880209.2017.131090728395583 DaiW.WuY.BiJ.WangJ.WangS.KongW.et al. (2018). Antiviral"/>
 <result pre="al. (2018). Antiviral effect of Retro-2.1 against Herpes simplex virus" exact="type 2" post="in vitro.J. Microbiol. Biotechnol.28849–859. 10.4014/jmb.1712.1205229847864 DuraffourS.LorenzoM. M.ZollerG.TopalisD.GrosenbachD.HrubyD. E.et al."/>
 <result pre="al. (2015). ST-246 is a key antiviral to inhibit the" exact="viral" post="F13L phospholipase, one of the essential proteins for orthopoxvirus"/>
 <result pre="W.ReynoldsM. G.BriandS.et al. (2018). Emergence of Monkeypox - West and" exact="Central" post="Africa, 1970-2017.MMWR Morb. Mortal. Wkly. Rep.67306–310. 10.15585/mmwr.mm6710a529543790 EngelstadM.SmithG. L."/>
 <result pre="1970-2017.MMWR Morb. Mortal. Wkly. Rep.67306–310. 10.15585/mmwr.mm6710a529543790 EngelstadM.SmithG. L. (1993). The" exact="vaccinia" post="virus 42-kDa envelope protein is required for the envelopment"/>
 <result pre="for virus virulence.Virology194627–637. 8503178 ErezN.AchdoutH.MilrotE.SchwartzY.Wiener-WellY.ParanN.et al. (2019). Diagnosis of imported" exact="monkeypox" post="Israel, 2018.Emerg. Infect. Dis.25980–983. 10.3201/eid2505.19007630848724 FennerF.NakanoJ. H. (1988). &quot;Poxviridae:"/>
 <result pre="FennerF.NakanoJ. H. (1988). &quot;Poxviridae: the poxviruses,�? in Laboratory Diagnosis of" exact="Infectious" post="Diseases Principles and Practice: VOLUME II Viral, Rickettsial, and"/>
 <result pre="H. (1988). &quot;Poxviridae: the poxviruses,�? in Laboratory Diagnosis of Infectious" exact="Diseases" post="Principles and Practice: VOLUME II Viral, Rickettsial, and Chlamydial"/>
 <result pre="E. (2011). Development of the small-molecule antiviral ST-246 as a" exact="smallpox" post="therapeutic.Future Virol.6653–671. 21837250 HarrisonK.HagaI. R.Pechenick JowersT.JasimS.CintratJ. C.GilletD.et al. (2016)."/>
 <result pre="smallpox therapeutic.Future Virol.6653–671. 21837250 HarrisonK.HagaI. R.Pechenick JowersT.JasimS.CintratJ. C.GilletD.et al. (2016)." exact="Vaccinia" post="virus uses retromer-independent cellular retrograde transport pathways to facilitate"/>
 <result pre="of the reservoir: phenotypic and genotypic characterization of a novel" exact="cowpox" post="virus isolated from a common vole.J. Virol.8910959–10969. 10.1128/JVI.01195-1526311891 JohnsonM."/>
 <result pre="Virol.8910959–10969. 10.1128/JVI.01195-1526311891 JohnsonM. C.DamonI. K.KaremK. L. (2008). A rapid, high-throughput" exact="vaccinia" post="virus neutralization assay for testing smallpox vaccine efficacy based"/>
 <result pre="(2008). A rapid, high-throughput vaccinia virus neutralization assay for testing" exact="smallpox" post="vaccine efficacy based on detection of green fluorescent protein.J."/>
 <result pre="Methods15014–20. 10.1016/j.jviromet.2008.02.00918387679 KaufmannS. H. E.DorhoiA.HotchkissR. S.BartenschlagerR. (2018). Host-directed therapies for" exact="bacterial" post="and viral infections.Nat. Rev. Drug Discov.1735–56. 10.1038/nrd.2017.16228935918 LanaveG.DowgierG.DecaroN.AlbaneseF.BrogiE.ParisiA.et al."/>
 <result pre="KaufmannS. H. E.DorhoiA.HotchkissR. S.BartenschlagerR. (2018). Host-directed therapies for bacterial and" exact="viral" post="infections.Nat. Rev. Drug Discov.1735–56. 10.1038/nrd.2017.16228935918 LanaveG.DowgierG.DecaroN.AlbaneseF.BrogiE.ParisiA.et al. (2018). Novel"/>
 <result pre="Drug Discov.1735–56. 10.1038/nrd.2017.16228935918 LanaveG.DowgierG.DecaroN.AlbaneseF.BrogiE.ParisiA.et al. (2018). Novel Orthopoxvirus and lethal" exact="disease" post="in cat.Italy. Emerg. Infect. Dis241665–1673. 10.3201/eid2409.17128330124195 LedermanE. R.DavidsonW.GroffH. L.SmithS."/>
 <result pre="Emerg. Infect. Dis241665–1673. 10.3201/eid2409.17128330124195 LedermanE. R.DavidsonW.GroffH. L.SmithS. K.WarkentienT.LiY.et al. (2012)." exact="Progressive" post="vaccinia: case description and laboratory-guided therapy with vaccinia immune"/>
 <result pre="al. (2012). Progressive vaccinia: case description and laboratory-guided therapy with" exact="vaccinia" post="immune globulin ST-246, and CMX001.J. Infect. Dis.2061372–1385. 10.1093/infdis/jis51022904336 LinK.GallayP."/>
 <result pre="ST-246, and CMX001.J. Infect. Dis.2061372–1385. 10.1093/infdis/jis51022904336 LinK.GallayP. (2013). Curing a" exact="viral infection" post="by targeting the host: the example of cyclophilin inhibitors.Antiviral"/>
 <result pre="and CMX001.J. Infect. Dis.2061372–1385. 10.1093/infdis/jis51022904336 LinK.GallayP. (2013). Curing a viral" exact="infection" post="by targeting the host: the example of cyclophilin inhibitors.Antiviral"/>
 <result pre="dissemination of vaccinia.J. Gen. Virol.5089–100. 7441216 RealegenoS.PuschnikA. S.KumarA.GoldsmithC.BurgadoJ.SambharaS.et al. (2017)." exact="Monkeypox virus" post="host factor screen using haploid cells identifies essential role"/>
 <result pre="W.GrahamM. B.RegneryR. L.SotirM. J.WegnerM. V.et al. (2004). The detection of" exact="monkeypox" post="in humans in the Western Hemisphere.N. Engl. J. Med.350342–350."/>
 <result pre="to the trans-Golgi network enables membrane wrapping and egress of" exact="vaccinia" post="virus virions.J. Virol.908891–8905. 10.1128/JVI.01114-1627466413 SmithG. L.VanderplasschenA.LawM. (2002). The formation"/>
 <result pre="SmithG. L.VanderplasschenA.LawM. (2002). The formation and function of extracellular enveloped" exact="vaccinia" post="virus.J. Gen. Virol.832915–2931. 10.1099/0022-1317-83-12-291512466468 SmithS. K.SelfJ.WeissS.CarrollD.BradenZ.RegneryR. L.et al. (2011)."/>
 <result pre="10.1099/0022-1317-83-12-291512466468 SmithS. K.SelfJ.WeissS.CarrollD.BradenZ.RegneryR. L.et al. (2011). Effective antiviral treatment of" exact="systemic" post="orthopoxvirus disease: ST-246 treatment of prairie dogs infected with"/>
 <result pre="systemic orthopoxvirus disease: ST-246 treatment of prairie dogs infected with" exact="monkeypox" post="virus.J. Virol.859176–9187. 10.1128/JVI.02173-1021697474 SpoonerR. A.SmithD. C.EastonA. J.RobertsL. M.LordJ. M."/>
 <result pre="P.HsuC. H.WerleZ. R.OlsonL. E.CooperM. P.CastrodaleL. J.et al. (2017). Novel Orthopoxvirus" exact="Infection" post="in an Alaska Resident.Clin. Infect. Dis.641737–1741. 10.1093/cid/cix21928329402 VaughanA.AaronsE.AstburyJ.BalasegaramS.BeadsworthM.BeckC. R.et"/>
 <result pre="Infect. Dis.641737–1741. 10.1093/cid/cix21928329402 VaughanA.AaronsE.AstburyJ.BalasegaramS.BeadsworthM.BeckC. R.et al. (2018). Two cases of" exact="monkeypox" post="imported to the United Kingdom, September 2018.Euro. Surveill.2310.2807/1560-7917.ES.2018.23.38.180050930255836 VoraN."/>
 <result pre="Kingdom, September 2018.Euro. Surveill.2310.2807/1560-7917.ES.2018.23.38.180050930255836 VoraN. M.LiY.GeleishviliM.EmersonG. L.KhmaladzeE.MaghlakelidzeG.et al. (2015). Human" exact="infection" post="with a zoonotic orthopoxvirus in the country of Georgia.N."/>
 <result pre="J. Med.3721223–1230. 10.1056/NEJMoa140764725806914 WolffeE. J.IsaacsS. N.MossB. (1993). Deletion of the" exact="vaccinia" post="virus B5R gene encoding a 42-kilodalton membrane glycoprotein inhibits"/>
</results>
